26Health, a provider of primary care and mental health services in the Southeast USA, announced on Friday that it has acquired Optimal Integrative Care, a medical practice in the West Midtown/Buckhead area of Atlanta, Georgia.
26Health said that this acquisition reflects its continued commitment to expanding access to high-quality, patient-centred healthcare and extends its integrated care model to more communities throughout the region. The expansion also strengthens access to specialised infectious disease and primary care services for patients in Atlanta, while further supporting 26Health's growing network in the Southeast.
Following the acquisition, 26Health will assume full ownership and operational management of Optimal Integrative Care. The practice will continue operating under the Optimal Integrative Care name, and patients can expect uninterrupted care, with no disruption to scheduled appointments, medical records, or ongoing treatment plans.
As part of the 26Health network, Optimal Integrative Care gains access to expanded clinical resources, enhanced services, and a broader network of healthcare providers.
Elaris FlexCo signs global licence agreement with Valneva
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
26Health acquires Optimal Integrative Care
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Aditxt acquires Ignite Proteomics to enhance cancer therapy selection
Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
Andel launches new direct-to-employer medication platform for GLP-1s
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
NASA awards Redwire USD4m to advance drug development in microgravity
Elicera Therapeutics receives Japanese patent allowance for ELC-401 CAR T-cell candidate